scPharmaceuticals Inc. (SCPH)
2.49
0.16 (6.87%)
At close: Apr 02, 2025, 3:59 PM
2.43
-2.49%
After-hours: Apr 02, 2025, 06:30 PM EDT
6.87% (1D)
| Bid | 2.41 |
| Market Cap | 124.6M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.91 |
| PE Ratio (ttm) | -1.3 |
| Forward PE | -3.03 |
| Analyst | Buy |
| Ask | 2.44 |
| Volume | 495,595 |
| Avg. Volume (20D) | 419,671 |
| Open | 2.28 |
| Previous Close | 2.33 |
| Day's Range | 2.20 - 2.49 |
| 52-Week Range | 2.20 - 5.65 |
| Beta | 0.39 |
About SCPH
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 17, 2017
Employees 162
Stock Exchange NASDAQ
Ticker Symbol SCPH
Analyst Forecast
According to 3 analyst ratings, the average rating for SCPH stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 381.93% from the latest price.
Stock ForecastsNext Earnings Release
scPharmaceuticals Inc. is scheduled to release its earnings on May 13, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 weeks ago
-1.89%
scPharmaceuticals shares are trading higher after ...
Unlock content with
Pro Subscription
3 months ago
-5.82%
ScPharmaceuticals shares are trading lower after the company disclosed observed variability during shelf-life testing in one lot of its SCP-111 combination product. This may result in the submission occurring later in 2025.
